Please see full prescribing and safety information, including boxed warning, for CLINDAMYCIN single-dose vials and CLINDAMYCIN pharmacy bulk package bottles.
Available in:
- 300 mg per 2 mL single-dose vials
- 600 mg per 4 mL single-dose vials
- 900 mg per 6 mL single-dose vials
- 9,000 mg per 60 mL pharmacy bulk package bottles
Benefits:
- AP Rated
- Not made with natural rubber latex
Downloads:
CLINDAMYCIN Injection, USP*
Brand Name Equivalent: CLEOCIN® (CLEOCIN is a registered trademark of Pharmacia & Upjohn Company, LLC.)
Therapeutic Category: Anti-Infective
PreventIV Measures® Features:
- Easy-to-read drug name and dosage strength to aid in identifying the right product
- Bar codes included on the vial and carton for ease of scanning
- Unique label design to help products stand out on the shelf
- Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
| NDC #25021 |
Description | Strength | Fill Volume |
Concentration | Container Size |
Closure | Unit of Sale |
| 115-02 | Glass Vial | 300 mg | 2 mL | 150 mg per mL | 2 mL | 13 mm | 25 |
| 115-04 | Glass Vial | 600 mg | 4 mL | 150 mg per mL | 5 mL | 20 mm | 25 |
| 115-06 | Glass Vial | 900 mg | 6 mL | 150 mg per mL | 10 mL | 20 mm | 25 |
| 115-51 | Glass Vial | 9,000 mg | 60 mL | 150 mg per mL | 100 mL | 20 mm | 1 |
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
Because clindamycin injection therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
